Recent News for BVXV - BiondVax Pharmaceuticals Ltd.

Date Title
Oct 7 BiondVax Receives €4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial
Aug 28 Biondvax Pharmaceuticals reports Q2 results
Aug 28 BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
Aug 1 BVXV: Raises $20 Million; Phase 3 Trial Fully Funded…
Jul 16 BiondVax rights offering fully subscribed at $20M
Jul 16 BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
Jun 26 European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to €24million
Jun 18 Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan
Jun 12 BVXV: Rights Offering to Finance Company Through Phase 3 Trial Results…
Jun 10 BiondVax sets terms for rights offering
Jun 10 BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process
May 30 Biondvax Pharmaceuticals reports Q1 results
May 30 BiondVax Announces First Quarter 2019 Financial Results
May 13 BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
Apr 30 Biondvax Pharmaceuticals reports FY results
Apr 30 BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
Apr 24 The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova
Apr 22 European Investment Bank (EIB) Extends Financing Agreement to €24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial
Back to the Main BVXV Page...